SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:kth-121606"
 

Sökning: onr:"swepub:oai:DiVA.org:kth-121606" > Targeting HMG-CoA r...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006605naa a2200541 4500
001oai:DiVA.org:kth-121606
003SwePub
008130503s2013 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:ee10e5c2-43af-428f-acc8-3c45054b1851
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-1216062 URI
0247 a https://doi.org/10.1007/s10549-013-2473-62 DOI
0247 a https://lup.lub.lu.se/record/36284202 URI
040 a (SwePub)kthd (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Bjarnadottir, Olöfu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-oba
2451 0a Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
264 c 2013-03-08
264 1b Springer Science and Business Media LLC,c 2013
338 a print2 rdacarrier
500 a QC 20130506
520 a Lipophilic statins purportedly exert anti-tumoral effects on breast cancer by decreasing proliferation and increasing apoptosis. HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, is the target of statins. However, data on statin-induced effects on HMGCR activity in cancer are limited. Thus, this pre-operative study investigated statin-induced effects on tumor proliferation and HMGCR expression while analyzing HMGCR as a predictive marker for statin response in breast cancer treatment. The study was designed as a window-of-opportunity trial and included 50 patients with primary invasive breast cancer. High-dose atorvastatin (i.e., 80 mg/day) was prescribed to patients for 2 weeks before surgery. Pre- and post-statin paired tumor samples were analyzed for Ki67 and HMGCR immunohistochemical expression. Changes in the Ki67 expression and HMGCR activity following statin treatment were the primary and secondary endpoints, respectively. Up-regulation of HMGCR following atorvastatin treatment was observed in 68 % of the paired samples with evaluable HMGCR expression (P = 0.0005). The average relative decrease in Ki67 expression following atorvastatin treatment was 7.6 % (P = 0.39) in all paired samples, whereas the corresponding decrease in Ki67 expression in tumors expressing HMGCR in the pre-treatment sample was 24 % (P = 0.02). Furthermore, post-treatment Ki67 expression was inversely correlated to post-treatment HMGCR expression (rs = -0.42; P = 0.03). Findings from this study suggest that HMGCR is targeted by statins in breast cancer cells in vivo, and that statins may have an anti-proliferative effect in HMGCR-positive tumors. Future studies are needed to evaluate HMGCR as a predictive marker for the selection of breast cancer patients who may benefit from statin treatment.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a HMGCR
653 a Ki67
653 a Statins
653 a Breast cancer
653 a Mevalonate pathway
7001 a Romero, Quinciu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kkem-qro
7001 a Bendahl, Pär-Olau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-pbe
7001 a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji
7001 a Rydén, Lisau Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)pat-lry
7001 a Loman, Niklasu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-nlo
7001 a Uhlén, Mathiasu KTH,Proteomik,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:kth)u1dulvmw
7001 a Johannesson, Henriku Atlas Antibodies AB, AlbaNova University Center, Stockholm, Sweden4 aut0 (Swepub:kth)u1t5vc8g
7001 a Rose, Carstenu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-cro
7001 a Grabau, Dortheu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)med-dgu
7001 a Borgquist, Signeu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)ront-sbo
7102 a Bröstcancer-genetikb Sektion I4 org
7730 t Breast Cancer Research and Treatmentd : Springer Science and Business Media LLCg 138:2, s. 499-508q 138:2<499-508x 0167-6806x 1573-7217
8564 u http://www.ncbi.nlm.nih.gov/pubmed/23471651?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1007/s10549-013-2473-6y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-121606
8564 8u https://doi.org/10.1007/s10549-013-2473-6
8564 8u https://lup.lub.lu.se/record/3628420

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy